Halozyme Therapeutics (HALO) Tops Q4 EPS by 1c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.99 +0.64%
Revenue Growth %: +23.1%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +23.1%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.42, $0.01 better than the analyst estimate of $0.41. Revenue for the quarter came in at $102 million versus the consensus estimate of $100.29 million.
GUIDANCE:
Halozyme Therapeutics sees FY2022 EPS of $2.05-$2.20, versus the consensus of $2.18. Halozyme Therapeutics sees FY2022 revenue of $530-560 million, versus the consensus of $554.2 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
- Accenture downgraded by TD Cowen on AI concerns
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
